Precision oncology in advanced cancer patients improves overall survival
Share

IMAGE: Figure 3: Costs per patient among the health system health plan members in the last 3 months of life, by site of care. Standard Tx: Select Health members with relevant… view more 

Credit: Lincoln D. Nadauld, email: [email protected]

The use of advanced molecular diagnostic technologies, such as Next-Generation Sequencing based gene panel testing, to select targeted therapies in advanced cancer patients is known as precision oncology.

In order to evaluate the impact of precision cancer medicine beyond the PFS window and to determine the degree to which any survival or cost advantages persisted, they conducted a follow up analysis on the subset of 44 patients from the original study to measure overall survival, average total healthcare costs, and resource utilization over the entire observation period, from the start of the study through either death or last observed encounter.

Building on a matched cohort study of 44 patients with metastatic cancer who received all of their care within a single institution, researchers from the Precision Genomics & Navican Genomics at Intermountain Healthcare and the Division of Oncology, Department of Medicine, at Stanford University School of Medicine evaluated the overall survival and healthcare costs for each patient.

A separate analysis

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD